The activation of Sirt3, by increased levels of NAD+ induced by CD38 deficiency, activates AMPK, which suppresses Ang-II-induced cardiac hypertrophy by inhibiting the AKT-glycogen synthase kinase3β (GSK3β)-NFATc pathway [113]. Here, SIRT3 is linked to cardiac hypertrophy.